Soleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients

Soleno Therapeutics Inc SLNO has announced the presentation of behavioral outcomes data from its ongoing open-label extension study (C602) of DCCR (diazoxide choline) for Prader-Willi Syndrome (PWS).
Prader-Willi Syndrome is characterized by a chronic feeling of insatiable hunger that severely diminishes the quality of life.
Data were presented at the Pediatric Academic Societies (PAS) 2021 Virtual Annual Meeting.
Through the 48 interviews, 39 behavioral outcomes were identified in seven outcome domains, with an average of 22±5.9 behaviors reported.
The three most frequently reported domains were Food-seeking Behaviors, Mealtime Behaviors, and Daily Life Behaviors.
83% of the participants reported a positive change in one or more behavioral outcomes on DCCR, more than 70% reported positive changes in one quarter or more of behaviors. In comparison, 48% reported positive changes in more than half of behaviors.
23% of participants reported a negative behavior change, and 6% reported more than one negative change
Price Action: SLNO shares are down 0.8% at $1.18 in the premarket session on the last check Tuesday.